Hepatitis C Knowledge and Recent Diagnosis Affect Hepatitis C Treatment Willingness in Persons Living With HIV

Edward R Cachay1, Francesca J Torriani1, Lucas Hill2

  • 1Department of Medicine, Division of Infectious Diseases and Global Public Health, UC San Diego, San Diego, CA.

Insights

Low hepatitis C (HCV) knowledge and long-term infection decrease willingness to start HCV treatment in people living with HIV (PLWH). Improving HCV knowledge is key to increasing treatment uptake among PLWH.

Area of Science:

  • Infectious Diseases
  • Hepatology
  • Public Health

Background:

  • People living with HIV (PLWH) often have co-infection with hepatitis C virus (HCV).
  • Understanding factors influencing HCV treatment willingness is crucial for effective care in this population.
  • Health literacy and specific HCV knowledge may impact treatment decisions.

Purpose of the Study:

  • To assess the impact of health literacy and hepatitis C (HCV) knowledge on HCV treatment willingness among people living with HIV (PLWH).
  • To identify predictors of low health literacy, HIV knowledge, and HCV knowledge.
  • To determine factors associated with willingness to initiate HCV treatment.

Main Methods:

  • Cross-sectional analysis of 151 PLWH co-infected with HCV.
  • Utilized health literacy, HIV literacy, and HCV knowledge inventories.
  • Employed mixed-model linear and logistic regression to identify predictors.

Main Results:

  • Prevalence of low health literacy, HIV knowledge, and HCV knowledge was 10%, 32%, and 29%, respectively.
  • Low HCV knowledge was associated with female sex, non-White ethnicity, and longer duration of HCV diagnosis.
  • Living with HCV for a decade decreased willingness to treat (OR: 0.23), while high HCV knowledge increased it (OR: 1.27).

Conclusions:

  • Low hepatitis C (HCV) knowledge is a significant barrier to treatment initiation in people living with HIV (PLWH).
  • Longer duration of HCV infection (≥10 years) is associated with reduced willingness to undergo treatment.
  • Interventions to improve HCV knowledge and address long-standing infections are needed to enhance treatment uptake.
Abstract

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
48.4K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
80
Sexually Transmitted Infections01:26

Sexually Transmitted Infections

Sexually transmitted infections (STIs) are diseases transmitted primarily through unsafe sexual interactions. Bacteria, viruses, or parasites cause them and can result in severe health complications if untreated.ChlamydiaThe bacterium Chlamydia trachomatis is responsible for the disease Chlamydia, the most common STI in the United States. This peculiar pathogen requires human cells to reproduce, residing intracellularly. The initial infection often goes unnoticed because it typically does not...
574
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
76
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
498
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
100